Abstract
Regenerative treatment with enamel matrix proteins (EMD) has been shown to promote regeneration in intrabony periodontal defects. However, up to now various postoperative regimens such as the routine administration of nonsteroidal anti-inflammatory drugs (NSAIDs) were often used in combination with enamel matrix proteins. Therefore, it cannot be excluded that the results might have been influenced by the effect of the postoperative medication. The aim of this randomized, controlled, blinded, clinical investigation was to determine the effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony periodontal defects following regenerative periodontal surgery with EMD. Twenty two patients, each of whom exhibited one deep intrabony defect, were randomly treated with either EMD plus a selective cyclo-oxygenase-2 (COX-2) inhibitor (test) or with EMD alone (control). The postoperative regimen consisted of oral administration of 12.5 mg rofecoxib twice daily for 14 days. The following parameters were recorded at baseline and at 6 months by the same calibrated and blinded investigator: plaque index (Pl), gingival index (GI), bleeding on probing (BOP), pocket depth (PD), gingival recession (GR), and clinical attachment level (CAL). Power analysis to determine superiority of the anti-inflammatory treatment showed that the available sample size would yield 70% power to detect a 1 mm difference. No statistical significant differences in any of the investigated parameters between the two groups were observed at baseline. The results show that, in the test group, mean PD decreased from 8.7±1.4 mm to 4.7±2.0 mm (P<0.001) and mean CAL from 9.7±2.0 mm to 6.5±2.1 mm (P<0.001). In the control group, mean PD decreased from 8.6±1.6 mm to 4.7±1.8 mm (P<0.001) and mean CAL from 9.5±1.6 mm to 6.5±2.2 mm (P<0.001). There were no significant differences between the two groups in any of the investigated parameters. Within the limits of the present study, it can be concluded that the systemic administration of a selective COX-2 inhibitor following regenerative periodontal surgery with EMD did not result in additional clinical improvements when compared to treatment with EMD alone.
Similar content being viewed by others
References
Bezerra MM, De Lima V, Alencar VBM, Vieira IB, Brito GAC, Ribeiro RA, Rocha FAC (2000) Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 71:1009–1014
Gunsolley JC, Elswick RK, Davenport JM (1998) Equivalence and superiority trials in regeneration clinical trials. J Periodontol 69:521–527
Hammarström L, Heijl L, Gestrelius S (1997) Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 24:669–677
Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E (2000) Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), Ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 43:370–377
Heijl L, Heden G, Svardström G, Östgren A (1997) Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects. J Clin Periodontol 24:705–714
Holzhausen M, Rossa C, Marcantonio E, Nassar PO, Spolidorio DMP, Spolidorio LC (2002) Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. J Periodontol 73:1030–1036
Howell TH, Williams RC (1993) Nonsteroidal anti-inflammatory drugs as inhibitors of periodontal disease progression. Crit Rev Oral Biol Med 4:177–196
Löe H (1967) The Gingival Index, the Plaque Index and the Retention Index system. J Periodontol 38:610–616
Lyngstadaas SP, Lundberg E, Ekdahl H, Andersson C, Gestrelius S (2001) Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative. J Clin Periodontol 28:181–188
Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B (1999) Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Therapeut 21:943–953
Morton RS, Dongari-Bagtzoglou AI (2001) Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 72:461–469
Salvi GE, Williams RC, Offenbacher S (1997) Nonsteroidal antiinflammatory drugs as adjuncts in the management of periodontal diseases and peri-implantitis. Curr Opin Periodontol 4:51–58
Sculean A, Donos N, Windisch P, Gera I, Brecx M, Reich E, Karring T (1999) Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. J Periodont Res 34:310–322
Sculean A, Donos N, Brecx M, Reich E, Karring T (2000) Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. An experimental study in monkeys. J Clin Periodontol 27:466–472
Van der Pauw MT, van den Bos T, Everts V, Beertsen W (2000) Enamel matrix-derived protein stimulates attachment of periodontal ligament fibroblasts and enhances alkaline phosphatase activity and transforming growth factor β1 release of periodontal ligament and gingival fibroblasts. J Periodontol 71:31–43
Wennström JL, Lindhe J (2002) Some effects of enamel matrix proteins on wound healing in the dento-gingival region. J Clin Periodontol 29:9-14
Williams RC, Jeffcoat MK, Howell TH, Rolla A, Stubbs D, Teoh KW, Reddy MS, Goldhaber P (1989) Altering the progression of human alveolar bone loss with the nonsteroidal anti-inflammatory drug flurbiprofen. J Periodontol 60:485–490
Yukna RA, Mellonig JT (2000) Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10-case series. J Periodontol 71:752–759
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sculean, A., Berakdar, M., Donos, N. et al. The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. Clin Oral Invest 7, 108–112 (2003). https://doi.org/10.1007/s00784-003-0200-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-003-0200-0